Antiviral agents

Fields Virology: Sixth Edition

Volumn 1, Issue , 2013, Pages

  Coen, Donald M ^a   Richman, Douglas D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84908240567     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (405)

1. Aduma PP, Connelly MC, Srinivas RV, et al. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates. Mol Pharmacol 1995;47:816-822.
2. Alian A, Griner SL, Chiang V, et al. Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs. Proc Natl Acad Sci U S A 2009;106:8192-8197.
3. Anderson KP, Fox MC, Brown-Driver V, et al. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob Agent Chemother 1996;40:2004-2011.
4. Appelt K. Crystal structures of HIV-1 protease-inhibitor complexes. Perspect Drug Disc Design 1993;1:23-48.
5. Arion D, Kaushik N, McCormick S, et al. Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998;37:15908-15917.
6. Atkinson WL, Arden NH, Patriarca PA, et al. Amantadine prophylaxis during an institutional outbreak of type A (H1N1) influenza. Arch Intern Med 1986;146:1751-1756.
7. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
8. Azad RF, Driver VB, Tanaka K, et al. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob Agents Chemother 1993;37:1945-1954.
9. Baba M, Nishimura O, Kanzaki N, et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci U S A 1999;96:5698-5703.
10. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-1217.
11. Baldanti F, Lurain N, Gerna G. Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs. Human Immunol 2004;65:403-409.
12. Baldanti F, Underwood MR, Stanat SC, et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996;70:1390-1395.
13. Balfour HH Jr, Bean B, Laskin OL, et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983;308:1448-1453.
14. Bartels DJ, Zhou Y, Zhang EZ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008;198:800-807.
15. Bean WJ, Threlkeld SC, Webster RG. Biologic potential of amantadine resistant influenza A virus in an avian model. J Infect Dis 1989;159:1050-1056.
16. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005;353:1374-1385.
17. Belshe RB, Hall Smith M, Hall CB, et al. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J virol 1988;62:1508-1512.
18. Bennett KK, DeGruttola VG, Marschner IC, et al. Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy. J AIDS 2002;31:20-26.
19. Besecker MI, Furness CL, Coen DM, et al. Expression of extremely low levels of thymidine kinase from an acyclovir-resistant herpes simplex virus mutant supports reactivation from latently infected mouse trigeminal ganglia. J Virol 2007;81:8356-8360.
20. Beutner KR, Friedman DJ, Forszpaniak C, et al. Valciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39:1546-1553.
21. Biron KK, Stanat SC, Sorrell JB, et al. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl]guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A 1985;82:2473-2477.
22. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010;328:1272-1275.
23. Boden D, Markowitz M. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 1998;42:2775-2783.
24. Boucher CAB, O'Sullivan E, Mulder JW, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992;165:105-110.
25. Boyer P, Sarafianos S, Arnold E, et al. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol 2001;75:4832-4842.
26. Bozzette SA, McCutchan JA, Spector SA, et al. A cross-sectional comparison of persons with syncytium- and non-syncyticum-inducing human immunodeficiency virus. J Infect Dis 1993;168:1993.
27. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005;366:1175-1181.
28. Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12:1735-1744.
29. Brown DG, Visse R, Sandhu G, et al. Crystal structures of the thymidine kinase from herpes simplex virus type-1 in complex with deoxythymidine and ganciclovir. Nat Struct Biol 1995;2:876-880.
30. Brown RS. Hepatitis C and liver transplantation. Nature 2005;436:973-978.
31. Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4+ lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999;103:1391-1398.
32. Buhles WC Jr, Mastre BJ, Tinker AJ, et al. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients. Rev Infect Dis 1988;10(Suppl. 3):S495-S506.
33. Bui M, Whttaker G, Helenius A. Effect of M1 protein and low pH on nuclear transport of influenza virus ribonucleoproteins. J Virol 1996;70:8391-8401.
34. Bukrinskaya AG, Vorkunova NK, Kornilayeva GV, et al. Influenza virus uncoating in infected cells and effect of rimantadine. J Gen Virol 1982;60:49-59.
35. Burmeister WP, Ruigrok RW, Cusack S. The 2.2 Å resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J 1992;11:49-56.
36. Cady SD, Schmidt-Rohr K, Wang J, et al. Structure of the amantadine binding site of influenza M2 proton channels in lipid bilayers. Nature 2010;463:689-692.
37. Cammack N, Rouse P, Marr CL, et al. Cellular metabolism of (-) enantiomeric 2'-deoxy-3'-thiacytidine. Biochem Pharmacol 1992;43:2059-2064.
38. Carrington M, Dean M, Martin MP, et al. Genetics of HIV-1 infection: chemokine receptor CCR5 polymorphism and its consequences. Hum Mol Genet 1999;8:1939-1945.
39. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997;276:960-964.
40. Champness JN, Bennett MS, Wien F, et al. Exploring the active site of herpes simplex virus type-1 thymidine kinase by X-ray crystallography of complexes with aciclovir and other ligands. Proteins 1998;32:350-361.
41. Chan DC, Fass D, Berger JM, et al. Core structure of gp41 from the HIV envelope protein. Cell 1997;89:263-273.
42. Chen C, Matthews TJ, McDanal CB, et al. A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implications for viral fusion. J Virol 1995;69:3771-3777.
43. Chen CH, Vasquez-Padua M, Cheng Y-C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991;39:625-628.
44. Chen S-H, Cook WJ, Grove KL, et al. Human thymidine kinase can functionally replace herpes simplex virus type 1 thymidine kinase for viral replication in mouse sensory ganglia and reactivation from latency upon explant. J Virol 1998;72:6710-6715.
45. Chen X, Tsiang M, Yu F, et al. Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors. J Mol Biol 2008;380:504-519.
46. Cheng Y-C, Dutschman GE, Bastow KF, et al. Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs. J Biol Chem 1987;262:2187-2189.
47. Cheng Y-C, Huang E-S, Lin J-C, et al. Unique spectrum of activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. Proc Natl Acad Sci U S A 1983;80:2767-2770.
48. Cherrington JM, Allen SJ, McKee BH, et al. Kinetic analysis of the interaction between the diphosphate of (S)-1-3-hydroxy-2(phosphonylmethoxy-propyl)cytosine, ddCTP, AZTTP, and FIAUTP with human DNA polymerases β and γ. Biochem Pharmacol 1994;48:1986-1988.
49. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 2009;15:893-900.
50. Chun T-W, Stuyver L, Mizel lSB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997;94:13193-13197.
51. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-459.
52. Cihlar T, Votruba I, Horska K, et al. Metabolism of 1-(S)-3-hydroxy-2-phosphonomethoxypropyl)cytosine (HPMPC) in human embryonic lung cells. Collect Czech Chem Commun 1992;57:661-672.
53. Cleland A, Watson HG, Robertson P, et al. Evolution of zidovudine resistance-associated genotypes in human immunodeficiency virus type 1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:6-18.
54. Coates JAV, Cammack N, Jenkinson HJ, et al. (-)-2'-deoxy-3'thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 1992;36:733-736.
55. Coates JAV, Cammack N, Jenkinson HJ, et al. The separated enantiomers of 2'-didexoxy-3'thiacytidine (BCH-189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother 1992;36:202-205.
56. Cocchi F, DeVico AL, Garzino-Demo A, et al. Identification of RANTES, MIP-1α, and MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-1815.
57. Coen DM. The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy. Antivir Res 1991;15:287-300.
58. Coen DM. Acyclovir-resistant, pathogenic herpesviruses. Trends Microbiol 1994;2:481-485.
59. Coen DM, Irmiere AF, Jacobson JG, et al. Low levels of herpes simplex virus thymidine- thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model. Virology 1989;168:221-231.
60. Coen DM, Schaffer PA. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc Natl Acad Sci U S A 1980;77:2265-2269.
61. Coffin JM. Population dynamics of HIV drug resistance. In: Richman DD, ed. Antiviral Drug Resistance. Chichester: John Wiley & Sons; 1996:279-303.
62. Cohen KA, Hopkins J, Ingraham RH, et al. Characterization of the binding site for nevirapine (BI-RG-587), a nonnucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase. J Biol Chem 1991;266:14670-14674.
63. Collins JA, Thompson MG, Paintsil E, et al. Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J Virol 2004;78:603-611.
64. Committee CC. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349:1413-1421.
65. Committee DC. Delta: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanozine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996;348:283-291.
66. Condra JH. Virological and clinical implications of resistance to HIV-1 protease inhibitors. Drug Resist Updat 1998;1:292-299.
67. Condra JH, Emini EA, Gotlib L, et al. Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse non-nucleoside inhibitors. Antimicrob Agents Chemother 1992;36:1441-1446.
68. Contreras AM, Hiasa Y, He W, et al. Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C replication system. J Virol 2002;76:8505-8517.
69. Cossarizza A, Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 2004;18:137-151.
70. Craig JC, Grief C, Mills JS, et al. Effects of a specific inhibitor of HIV proteinase (Ro 31-8959) on virus maturation in a chronically infected promonocytic cell line (U1). Antiviral Chem Chemother 1991;2:181-186.
71. Crawford SA, Clover RD, Abell TD, et al. Rimantadine prophylaxis in children: a follow-up study. Pediatr Infect Dis J 1988;7:379-383.
72. Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 2001;98:6895-6900.
73. Crotty S, Maag D, Arnold JJ, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000;6:1375-1379.
74. Crumpacker CS, Schnipper LE, Zaia JA, et al. Growth inhibition by acycloguanosine of herpesviruses isolated from human infections. Antimicrob Agents Chemother 1979;15:642-645.
75. Davies WL, Grunert RR, Haff RF, et al. Antiviral activity of 1-adamantanamine (amantadine). Science 1964;144:862-863.
76. de Jong MD, Bach VC, Phan TQ, et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 2005;352:686-691.
77. de Ronde A, van Dooren M, van Der Hoek L, et al. Establishment of new transmissible and drug-sensitive human immunodeficiency virus type 1 wild types due to transmission of nucleoside analogue-resistant virus. J Virol 2001;75:595-602.
78. Di Bisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903.
79. Diallo K, Götte M, Wainberg MA. Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2003;47:337-3383.
80. Dieterich DT, Kotler DP, Busch DF, et al. Ganciclovir treatment of cytomegalovirus colitis in AIDS: a randomized, double-blind, placebo-controlled multicenter study. J Infect Dis 1993;167:278-282.
81. Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982;307:580-584.
82. Domingo E, Gomez J. Quasispecies and its impact on viral hepatitis. Virus Res 2007;127:131-150.
83. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005;49:4721-4732.
84. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1999;396:690-695.
85. Douglas JM, Critchlow C, Benedetti J, et al. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection. N Engl J Med 1984;310:1551-1556.
86. Doyon L, Croteau G, Thibeault D, et al. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol 1996;70:3763-3769.
87. Drake JW, Holland JJ. Mutation rates among RNA viruses. Proc Natl Acad Sci U S A 1999;96:13910-13913.
88. Dubay J, Roberts S, Brody B, et al. Mutations in the lecuine zipper of HIV-1 transmembrane glycoprotein affect fusion and infectivity. J Virol 1992;66:4748-4756.
89. Duff KC, Ashley RH. The transmembrane domain of influenza A M2 protein forms amantadine-sensitive proton channels in planar lipid bilayers. Virology 1992;190:485-489.
90. Dunkle LM, Arvin AM, Whitley RJ, et al. A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med 1991;325:1539-1544.
91. Elion GB, Furman PA, Fyfe JA, et al. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine. Proc Natl Acad Sci U S A 1977;74:5716-5720.
92. Erickson JW, Meidhart DJ, Van Drie J, et al. Design, activity, and a 2.8 Å crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science 1990;249:527-533.
93. Eriksson B, Öberg B, Wahren B. Pyrophosphate analogs as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin. Biochim Biophys Acta 1982;696:115-123.
94. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.
95. Feld JJ, Hoofnagle JH. Mechanism of action of inteferon and ribavirin in treatment of hepatitis C. Nature 2005;436:967-972.
96. Feld JJ, Lutchman GA, Heller T, et al. Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology 2010;139:154-162.
97. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-517.
98. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
99. Fischl MA, Richman DD, Causey DM, et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA 1990;262:2405-2410.
100. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:185-191.
101. Florea NR, Maglio D, Nicolau DP. Pleconaril, a novel antipicornal agent. Pharmacotherapy 2003;23:339-348.
102. Franklin MC, Wang J, Steitz TA. Structure of the replicating complex of a pol α family DNA polymerase. Cell 2001;105:657-667.
103. Freed EO, Martin MA. HIVs and their replication. In: Knipe DM, Howley PM, Griffin DE, et al., eds. Fields Virology. 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2007.
104. Freitas VR, Smee DF, Chernow M, et al. Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses. Antimicrob Agents Chemother 1985;28:240-245.
105. Fried MW, Shiffman ML, Reddy RK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
106. Furman PA, de Miranda P, St. Clair MH, et al. Metabolism of acyclovir in virus-infected and uninfected cells. Antimicrob Agents Chemother 1981;20:518-524.
107. Furman PA, Fyfe JA, St. Clair MH, et al. Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase. Proc Natl Acad Sci U S A 1986;83:8333-8337.
108. Fyfe JA, Keller PM, Furman PA, et al. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound 9-(2-hydroxyethoxymethyl)guanine. J Biol Chem 1978;253:8721-9727.
109. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005;436:939-945.
110. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010;465:96-100.
111. Gao Q, Gu Z-X, Parniak MA, et al. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',-3'-dideoxyinosine. J Virol 1992;66:12-19.
112. Garcia-Perez J, Rueda P, Staropoli I, et al. New insights into the mechanisms whereby low molecular weight CCR5 ligands inhibit HIV-1 infection. J Biol Chem 2011;286:4978-4990.
113. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
114. Gelderblom H. Assembly and morphology of HIV: potential effects of structure on viral function. AIDS 1991;5:617-638.
115. Germershausen J, Bostedor R, Field AK, et al. A comparison of the antiviral agents 2'-nor-2'-deoxyguanosine and acyclovir: uptake and phosphorylation in tissue culture and kinetics of in vitro inhibition of viral and cellular DNA polymerases by their respective triphosphates. Biochem Biophys Res Commun 1983;116:360-367.
116. Ghany M, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology 2011;54(4):1433-1444.
117. Gibson SJ, Lindh JM, Riter TR, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cellular Immunol 2002;218:74-86.
118. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Updat 2002;5:88-114.
119. Gill VS, Lima VD, Zhang W, et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 2010;50:98-105.
120. Goudsmit J, deRonde A, de Rooij E, et al. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215. J Virol 1997;71:4479-4484.
121. Goudsmit J, deRonde A, Ho DD, et al. Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase. J Virol 1996;70:5662-5666.
122. Grey F, Sowa M, Collins P, et al. Characterization of a neurovirulent aciclovir-resistant variant of herpes simplex virus. J Gen Virol 2003;84:1403-1410.
123. Griffiths A, Chen S-H, Horsburgh BC, et al. Translational compensation of a frameshift mutation affecting herpes simplex virus thymidine kinase is sufficient to permit reactivation from latency. J Virol 2003;77:4703-4709.
124. Griffiths A, Coen DM. High-frequency phenotypic reversion and pathogenicity of an acyclovir-resistant herpes simplex virus mutant. J Virol 2003;77:2282-2286.
125. Gubareva LV, Bethell RC, Hart GJ, et al. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 1996;70:1818-1827.
126. Gubareva LV, Robinson MJ, Bethell RC, et al. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997;71:3385-3390.
127. Gubareva LV, Webster RG, Hayden FG. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 2001;45:3403-3408.
128. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
129. Haase AT. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol 1999;17:625-626.
130. Haase AT, Henry K, Zupancic M, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996;274:985-989.
131. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
132. Halfon P, Locarnini S. Hepatitis C virus resistance to protease inhibitors. J Hepatol 2011;55:192-206.
133. Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection: treatment with rimantidine. Pediatrics 1987;80:275-282.
134. Hamilton JD, Hartigan PM, Simberkoff MS, et al. A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. N Engl J Med 1992;326:437-443.
135. Hamirally S, Kamil JP, Ndassa-Colday YM, et al. Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. PLoS Pathog 2009;5:e1000275.
136. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-1090.
137. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200/μL or less. N Engl J Med 1997;337:725-733.
138. Harrigan PR, Bloor S, Larder BA. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro. J Virol 1998;72:3773-3778.
139. Hart GJ, Orr DC, Penn CR, et al. Effects of (-)-2'-deoxy-3'-thiacytidine (3TC) 5' triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother 1992;36:1688-1694.
140. Havlir DV, Schrier RD, Torriani FJ, et al. Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects. J Infect Dis 2000;182:1658-1663.
141. Hay AJ. Amantadine and rimantadine - mechanisms. In: Richman DD, ed. Antiviral Drug Resistance. Chichester: John Wiley & Sons; 1996:43-58.
142. Hay AJ, Wolstenholme AJ, Skehel JJ, et al. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985;4:3021-3024.
143. Hay AJ, Zambon MC, Wolstenholme AJ, et al. Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother 1986;18(Suppl. B):19-29.
144. Hayden FG. Amantadine and rimantadine resistance in influenza A viruses. Curr Opinion Infect Dis 1994;7:674-677.
145. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999;341:1336-1343.
146. Hayden FG, de Jong MD. Emerging influenza antiviral resistance threats. J Infect Dis 2011;203:6-10.
147. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med 2000;343:1282-1289.
148. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. N Engl J Med 1997;337:874-880.
149. Hayden FG, Sperber SJ, Belshe RB, et al. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 1991;35:1741-1747.
150. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999;282:1240-1246.
151. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand tranfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287:646-650.
152. He Z, He Y-S, Kim Y, et al. The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. J Virol 1997;71:405-411.
153. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-1680.
154. Hecht DW, Snydman DR, Crumpacker CS, et al. Ganciclovir for treatment of renal transplant-associated primary cytomegalovirus pneumonia. J Infect Dis 1988;157:187-190.
155. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200.
156. Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004;190:1627-1630.
157. Herrmann EC Jr, Herrmann JA. A working hypothesis - virus resistance development as an indicator of specific antiviral activity. Ann N Y Acad Sci 1977;284:632-637.
158. Hiraga N, Imamura M, Abe H, et al. Rapid emergence of telaprevir resistant hepatitis C virus strain from wild type clone in vivo. Hepatology 2011;54(3)781-788.
159. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society USA panel. Clin Infect Dis 2003;37:113-128.
160. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008;47:266-285.
161. Ho H-T, Woods KL, Bronson JJ, et al. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. Mol Pharmacol 1992;41:197-202.
162. Hofmann WP, Herrmann E, Sarrazin C, et al. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int 2008;28:1332-1343.
163. Holsinger LJ, Lamb RA. Influenza virus M2 integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. Virology 1991;183:32-43.
164. Horsburgh BC, Chen S-H, Hu A, et al. Recurrent acyclovir-resistant herpes simplex in an immunocompromised patient: can strain differences compensate for loss of thymidine kinase in pathogenesis? J Infect Dis 1998;178:618-625.
165. Horsburgh BC, Kollmus H, Hauser H, et al. Translational recoding induced by G-rich mRNA sequences that form unusual structures. Cell 1996;86:949-959.
166. Hostetler KY. Synthesis and antiviral evaluation of broad spectrum orally active analogs of cidofovir and other acyclic nucleoside phosphonates. In: DeClercq E, ed. Advances in Antiviral Drug Design. Vol 5. Oxford: Elsevier; 2007:167-184.
167. Huang L, Ishii KK, Zuccola H, et al. The enzymological basis for resistance of herpesvirus DNA polymerase mutants to acyclovir: relationship to the structure of α-like DNA polymerases. Proc Natl Acad Sci U S A 1999;96:447-452.
168. Huff JC, Bean B, Balfour HH Jr, et al. Therapy of herpes zoster with oral acyclovir. Am J Med 1988;85:84-89.
169. Hume AJ, Finkel JS, Kamil JP, et al. Phosphorylation of retinoblastoma protein by viral protein with cyclin-dependent kinase function. Science 2008;320:797-799.
170. Hwang CB, Chen HJ. An altered spectrum of herpes simplex virus mutations mediated by an antimutator DNA polymerase. Gene 1995;152:191-193.
171. Hwang CBC, Horsburgh B, Pelosi E, et al. A net +1 frameshift permits synthesis of thymidine kinase from a drug-resistant herpes simplex virus mutant. Proc Natl Acad Sci U S A 1994;91:5461-5465.
172. Hwang YT, Liu B-Y, Coen DM, et al. Effects of mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene on enzyme activities, viral replication, and replication fidelity. J Virol 1997;71:7791-7798.
173. Iglesias-Ussel M, Casado C, Yuste E, et al. In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. J Gen Virol 2002;83:93-101.
174. Ilsley DD, Lee S-H, Miller WH, et al. Acyclic guanosine analogues inhibit DNA polymerases α, δ, and ε with very different potencies and have unique mechanisms of action. Biochemistry 1995;34:2504-2510.
175. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998;129:94-99.
176. Irmiere AF, Manos MM, Jacobson JG, et al. Effect of an amber mutation in the herpes simplex virus thymidine kinase gene on polypeptide synthesis and stability. Virology 1989;168:210-220.
177. Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leaves virus severely compromised both in vitro and in vivo. Antiviral Res 2002;55:307-317.
178. Jabs DA, Enger C, Bartlett JG. Cytomegalovirus retinitis and acquired immunodeficiency syndrome. Arch Ophthalmol 1989;107:75-80.
179. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
180. Jing X, Ma C, Ohigashi Y, et al. Functional studies indicate amantadine binds to the pore of the influenza A virus M2 proton-selective ion channel. Proc Natl Acad Sci U S A 2008;105:10967-10972.
181. Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med 2010(18):156-163.
182. Joint United Nations Programme on HIV/AIDS. UNAIDS Report on the global AIDS epidemic. Available at: http://www.unaids.org/globalreport/Global_report.htm.
183. Jurk M, Heil F, Vollmer J, et al. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002;3:499.
184. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992;327:581-587.
185. Kamil JP, Hume AJ, Jurak I, et al. Human papillomavirus 16 E7 inactivator of retinoblastoma family proteins complements human cytomegalovirus lacking UL97 protein kinase. Proc Natl Acad Sci U S A 2009;106:16823-16828.
186. Kaufman H, Martola EL, Dohlman C. Use of 5-iodo-2'-deoxyuridine (IDU) in treatment of herpes simplex keratitis. Arch Ophthalmol 1962;68:235-239.
187. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverese transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci U S A 1992;89:1934-1938.
188. Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci U S A 1995;92:2484-2488.
189. Kempf DJ, Marsh KC, Paul DA, et al. Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1991;35:2209-2222
190. Kempf DJ, Norbeck DW, Codacovi L, et al. Structure-based, C2 symmetric inhibitors of HIV protease. J Med Chem 1990;33:2687-2689.
191. Kim CU, Lew W, Williams MA, et al. Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors. J Med Chem 1998;41:2451-2460.
192. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci U S A 1988;85:4686-4690.
193. Kohlstaedt LA, Wang J, Friedman JM, et al. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992;256:1783-1790.
194. Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998;4:953-956.
195. Kondru R, Zhang J, Ji C, et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 2008;73:789-800.
196. Lai MY, Kao JH, Yang PM, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996;111:1307-1312.
197. Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426:186-189.
198. Lanford RE, Guerra B, Lee H, et al. Antiviral effects and virus-host interactions in response to alpha interferon, gamma interferon, poly(I)-poly(C), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. J Virol 2003;77:1092-1104.
199. Larder BA, Darby G. Virus drug-resistance: mechanisms and consequences. Antiviral Res 1984;4:1-42.
200. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-1734.
201. Larder BA, Coates KE, Kemp SD. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J Virol 1991;65:5232-5236.
202. Larder BA, Kellam P, Kemp SD. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991;5:137-144.
203. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1155-1158.
204. Laver WG, Bischofberger N, Webster RG. Disarming flu viruses. Sci Am 1999;280:78-87.
205. Lawless MK, Barney S, Guthrie K, et al. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically active peptides from gp41. Biochemistry 1996;35:13697-13708.
206. Lederman MM, Miller V, Weller I, et al. A new approach for 'deep salvage' trials in advanced HIV infections. AIDS 2007;21:1503-1506.
207. Lederman MM, Penn-Nicholson A, Cho M, et al. Biology of CCR5 and its role in HIV infection and treatment. JAMA 2006;296:815-826.
208. Ledford RM, Collett MS, Pevear DC. Insights into the genetic basis for natural phenotypic resistance of human rhinoviruses to pleconaril. Antiviral Res 2005;68:135-138.
209. Lee H, Hanes J, Johnson KA. Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003;23:14711-14719.
210. Lennerstrand J, Hertogs K, Stammers DK, et al. Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants. J Virol 2001;75:7202-7205.
211. Li W-X, Escarpe PA, Eisenberg EJ, et al. Identification of GS4104 as an orally bioavailable prodrug of the influenza neuraminidase inhibitor GS4701. Antimicrob Agents Chemother 1998;42:647-653.
212. Libow LS, Neufeld RR, Olson E, et al. Sequential outbreak of influenza A and B in a nursing home: efficacy of vaccine and amantadine. J Am Geriatr Soc 1996;44:1153-1157.
213. Lin C, Kwong AD, Perni RB. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis NS3-4A serine protease. Infect Disord Drug Targets 2006;6:3-16.
214. Lin K, Perni RB, Kwong AD, et al. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother 2006;50:1813-1822.
215. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-626.
216. Little SJ. Transmission and prevalence of HIV resistance among treatment-naive subjects. Antiv Ther 2000;5:33-40.
217. Little SJ, Frost SD, Wong JK, et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 2008;82:5510-5518.
218. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
219. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992;358:160-162.
220. Liu C, Eichelberger MD, Compans RW, et al. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J Virol 1995;69:1099-1106.
221. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996;86:367-378.
222. Liu S, Knafels JD, Chang JS, et al. Crystal structure of the herpes simplex virus 1 DNA polymerase. J Biol Chem 2006;281:18193-18200.
223. Locarnini S, Bowden S. Drug resistance in antiviral therapy. Clin Liver Dis 2010;14:439-459.
224. Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007;146:87-95.
225. Lurain NS, Spafford LE, Thompson KD. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J Virol 1994;68:4427-4431.
226. Maag D, Castro C, Hong Z, et al. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 2001;276:46094-46098.
227. Maekawa S, Enomoto N. Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C. J Gastroenterol 2009;44:1009-1015.
228. Mai Le Q, Kiso M, Someya K, et al. Isolation of drug-resistant H5N1 virus. Nature 2005;437:1108.
229. Malcolm BA, Liu R, Lahser F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006;50:1013-1020.
230. Mammano F, Petit C, Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol 1998;72:7632-7637.
231. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-965.
232. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 1995;69:5087-5094.
233. Mar EC, Chiou JF, Cheng YC, et al. Human cytomegalovirus-induced DNA polymerase and its interaction with the triphosphates of 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-methyluracil, -5-iodocytosine, and -5-methylcytosine. J Virol 1985;56:846-851.
234. Martin DF, Dunn JP, Duker JS, et al. Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panel. Am J Opthalmol 1999;127:329-339.
235. Martin JL, Brown CE, Matthews-Davis N, et al. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994;38:2743-2749.
236. Martin K, Helenius A. Nuclear transport of influenza virus ribonucleoproteins: the viral matrix protein (M1) promotes export and inhibits import. Cell 1991;67:117-130.
237. Matsuoka-Aizawa S, Sato H, Hachiya A, et al. Isolation and molecular characterization of a nelfinavir (NFV)-resistant human immunodeficiency virus type 1 that exhibits NFV-dependent enhancement of replication. J Virol 2003;77:318-327.
238. McColl DJ, Chen X. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res 2010;85:101-118.
239. McCune JM, Loftus R, Schmidt DK, et al. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest 1998;101:2301-2308.
240. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-1492.
241. McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, et al. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-NeuAc2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother 1996;40:40-46.
242. McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010;50:912-919.
243. Mellors JW, Dutschman GE, Im G-J, et al. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase. Mol Pharmacol 1992;41:446-451.
244. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-954.
245. Mendel DB, Sidwell RW. Influenza virus resistance to neuraminidase inhibitors. Drug Resist Updat 1998;1:184-189.
246. Merluzzi VJ, Hargrave KD, Labadia M, et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 1990;250:1411-1413.
247. Mertz GJ, Critchlow CW, Benedetti J, et al. Double-blind placebo-controlled trial of oral acycolvir in first-episode genital herpes simplex virus infection. JAMA 1984;252:1147-1151.
248. Metzger C, Michel D, Schneider K, et al. Human cytomegalovirus UL97 kinase confers ganciclovir susceptibility to recombinant vaccinia virus. J Virol 1994;68:8423-8427.
249. Meyer PR, Matsuura SE, So AG, et al. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci U S A 1998;95:13471-13476.
250. Meyer PR, Matsuura SE, Tolun AA, et al. Effects of specific zidovudine-resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2002;46:1540-1545.
251. Miller V, Phillips AN, Rottman C, et al. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with treatment failure. J Infect Dis 1998;177:398-405.
252. Miller WH, Miller RL. Phosphorylation of acyclovir monophosphate by GMP kinase. J Biol Chem 1980;255:7204-7207.
253. Miller WH, Miller RL. Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem Pharmacol 1982;31:3879-3884.
254. Mindel A, Faherty A, Carney O, et al. Dosage and safety of long-term suppressive acyclovir therapy for recurrent genital herpes. Lancet 1988;1:926-928.
255. Mitsuya H, Weinhold KJ, Furman PA, et al. 3'-azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibts the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U S A 1985;82:7096-7100.
256. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996;2:760-766.
257. Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. JAMA 1998;279:930-937.
258. Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999;282:31-35.
259. Moore JP, Kuritzkes DR. A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr Opin HIV AIDS 2009;4:118-124.
260. Moore MR, Hamzeh FM, Lee FE-H, et al. Activity of (S)-1-(3-hydroxy-2-phosphonylmethoxy)propyl)]cytosine against human cytomegalovirus when administered as single-bolus dose and continuous infusion in in vitro cell culture perfusion system. Antimicrob Agents Chemother 1994;38:2404-2408.
261. Mori K, Ikeda M, Ariumi Y, et al. Mechanism of action of ribavirin in a novel hepatitis C virus replication cell system. Virus Res 2011;157:61-70.
262. Mulamba GB, Hu A, Azad RF, et al. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomiversen (ISIS 2922). Antimicrob Agents Chemother 1998;42:971-973.
263. Navia MA, Fitzgerald PM, McKeever BM, et al. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature 1989;337:615-620.
264. Neumann AU, Lam PYS, Dahlberg JE, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998;282:103-107.
265. Nilsen AE, Aasen T, Halsos AM, et al. Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes. Lancet 1982;2:571-573.
266. Njoroge FG, Chen KX, Shih N-Y, et al. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc Chem Res 2008;41:50-59.
267. Noble S, Faulds D. Ganciclovir: An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 1998;56:115-146.
268. Nolan D, Reiss P, Mallal S. Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opin Drug Saf 2005;4:201-218.
269. Odriozola L, Cruchaga C, Andréola M, et al. Non-nucleoside inhibitors of HIV-1 reverse transcriptase inhibit phosphorolysis and resensitize the 3'-azido-3'-deoxythymidine (AZT)-resistant polymerase to AZT-5'-triphosphate. J Biol Chem 2003;278:42710-42716.
270. Ohigashi Y, Ma C, Jing X, et al. An amantadine-sensitive chimeric BM2 ion channel of influenza B virus has implications for the mechanism of drug inhibition. Proc Natl Acad Sci U S A 2009;106:18775-18779.
271. Ostrander M, Cheng Y-C. Properties of herpes simplex virus type 1 and type 2 DNA polymerase. Biochim Biophys Acta 1980;609:232-245.
272. Otto MJ, Garber S, Winslow DL, et al. In vitro isolation and identification of HIV-1 variants with reduced sensitivity to C2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci U S A 1993;90:7543-7547.
273. Oxford JS, Potter CW. Aminoadamantane-resistant strains of influenza A2 virus. J Hyg Camb 1973;71:227-236.
274. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998;4:208-214.
275. Palese P, Compans RW. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoracetylneuraminic acid (FANA): mechanism of action. J Gen Virol 1976;33:159-163.
276. Palese P, Tobita K, Ueda M, et al. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 1974;61:397-410.
277. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008;105:3879-3884.
278. Parry J. Use of antiviral drug in poultry is blamed for drug resistant strains of avian flu. BMJ 2005;331:10.
279. Pawlotsky J-M. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011;53:1742-1751.
280. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387:188-191.
281. Perelson AS, Layden TJ. Ribavirin: Is it a mutagen for hepatitis C virus? Gastroenterology 2007;132:2050-2052.
282. Perelson AS, Neumann AU, Markowit M, et al. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifetime, and viral generation time. Science 1996;271:1582-1586.
283. Petit SC, Simsic J, Loeb DD, et al. Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. J Biol Chem 1991;266:14539-14547.
284. Pfeiffer JK, Kirkegaard K. A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci U S A 2003;100:7289-7294.
285. Pfeiffer JK, Kirkegaard K. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J Virol 2005;79:2346-2355.
286. Pielak RM, Oxenoid K, Chou JJ. Structural investigation of rimantadine inhibition of the AM2-BM2 chimera channel of influenza viruses. Structure 2011;19:1655-1663.
287. Pielak RM, Schnell JR, Chou JJ. Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc Natl Acad Sci U S A 2009;106:7379-7384.
288. Pillai SK, Good B, Pond SK, et al. Semen-specific genetic characteristics of human immunodeficiency virus type 1 env. J Virol 2005;79:1734-1742.
289. Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell 1992;69:517-528.
290. Pockros PJ. New direct-acting antivirals in the development for hepatitis C virus infection. Therap Adv Gastroenterol 2010;3:191-202.
291. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
292. Poorman RA, Tomaselli AG, Heirikson RL, et al. A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2 inferred from statistical analysis of an extended substrate data base. J Biol Chem 1991;266:14554-14561.
293. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352:1426-1432.
294. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-1313.
295. Price MA, Wallis CL, Lakhi S, et al. Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa. AIDS Res Hum Retroviruses 2011;27:5-12.
296. Prichard MN, Gao N, Jairath S, et al. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J Virol 1999;73:5663-5670.
297. Pulley S. CCR5 antagonists: from discovery to clinical efficacy. In: Neote K, Letts GL, Moser B, eds. Chemokine Biology-Basic Research and Clinical Application. Vol 2. Basel: Birkhauser; 2007:145-163.
298. Rameix-Welti MA, Enouf V, Cuvelier F, et al. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog 2008;4:e1000103.
299. Reardon JE. Herpes simplex virus type 1 and human DNA polymerase interactions with 2'-deoxyguanosine-5'-triphosphate analogues. J Biol Chem 1989;264:19039-19044.
300. Reardon JE, Spector T. Herpes simplex virus type 1 DNA polymerase. Mechanism of inhibition by acyclovir triphosphate. J Biol Chem 1989;264:7405-7411.
301. Reichard O, Norkans G, Fryden A, et al. Randomized double-blind, placebo-cotrolled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998;351:83-87.
302. Reichman RC, Badger GJ, Mertz GJ, et al. Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA 1984;251:2103-2107.
303. Reid R, Mar EC, Huang ES, et al. Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human alpha and human beta polymerases. A unique inhibition mechanism for 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate. J Biol Chem 1988;263:3898-3904.
304. Richman D, Rosenthal AS, Skoog M, et al. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother 1991;35:305-308.
305. Richman D, Shih C-K, Lowy I, et al. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci U S A 1991;88:11241-11245.
306. Richman DD. The implications of drug resistance for strategies of combination antiviral chemotherapy. Antiviral Res 1996;29:31-33.
307. Richman DD. Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor. Antiviral Ther 2001;6:83-88.
308. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of 3'-azido-3'deoxythymidine (azidothymidine) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:192-197.
309. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J Acquir Immune Defic Syndr 1990;3:743-746.
310. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-1666.
311. Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science 2009;323:1304-1307.
312. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived peptides. J Virol 1998;72:986-993.
313. Rittinger K, Divita G, Goody RS. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc Natl Acad Sci U S A 1995;92:8046-8049.
314. Rogers DW, Gamblin SJ, Harris BA, et al. The structure of unliganded reverse transcriptase from human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1995;92:1222-1226.
315. Romano KP, Ali A, Soumana D, et al. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLos Pathog 2012;8:e1002832.
316. Rong L, Perelson AS. Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling. Crit Rev Immunol 2010;30:131-148.
317. Safrin S. Herpes simplex virus and varicella zoster virus: nucleosides and foscarnet - clinical aspects. In: Richman DD, ed. Antiviral Drug Resistance. Chichester: John Wiley & Sons; 1996:103-122.
318. Safrin S, Crumpacker C, Chatis P, et al. A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. N Eng J Med 1991;325:551-555.
319. Safrin S, Kemmerly S, Plotkin B, et al. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis 1994;169:193-196.
320. Sarafianos SG, Das K, Clark AD Jr, et al. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with β-branched amino acids. Proc Natl Acad Sci U S A 1999;96:10027-10032.
321. Saral R, Ambinder RF, Burns WH, et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med 1983;99:773-776.
322. Saral R, Burns WH, Laskin OL, et al. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981;305:63-67.
323. Sarisky RT, Nguyen TT, Duffy KE, et al. Difference in incidence of spontaneous mutations between herpes simplex virus types 1 and 2. Antmicrob Agents Chemother 2000;44:1524-1529.
324. Sarisky RT, Quail MR, Clark PE, et al. Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir. J Virol 2001;75:1761-1769.
325. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010;138:447-462.
326. Sasadeusz JJ, Sacks SL. Spontaneous reactivation of thymidine kinase-deficient, acyclovir-resistant type 2 herpes simplex virus: masked heterogeneity or reversion? J Infect Dis 1996;174:476-482.
327. Schaeffer HJ, Beauchamp L, de Miranda P, et al. 9-(2-hydroxyethoxymethyl)guanine activity against viruses of the herpes group. Nature 1978;272:583-585.
328. Scheidel LM, Durbin RK, Stollar V. Sindbis virus mutants resistant to mycophenolic acid and ribavirin. Virology 1987;158:1-7.
329. Schinazi RF, Chu CK, Peck A, et al. Activities of the four optical isomers of 2'-3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lympocytes. Antimicrob Agents Chemother 1992;36:672-676.
330. Schnell JR, Chou JJ. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 2008;451:591-595.
331. Seifer M, Hamatake RK, Colonno RJ, et al. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998;42:3200-3208.
332. Selmi B, Deval J, Alvarez K, et al. The Y181C substitution in 3'-azido-3'-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer. J Biol Chem 2003;278:40464-40472.
333. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-1024.
334. Shimakami T, Welsch C, Yamane D, et al. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Gastroenterology 2011;140:667-675.
335. Shirasaka T, Yarchoan R, O'Brien MC, et al. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: An in vitro comparative study. Proc Natl Acad Sci U S A 1993;90:562-566.
336. Smee DF, Martin JC, Verheyden JPH, et al. Anti-herpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2propoxymethyl)guanine. Antimicrob Agents Chemother 1983;23:676-682.
337. Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011;53:763-773.
338. Spence RA, Kati WM, Anderson KS, et al. Mechanism of inhibition of HIV-1 reverse transcriptase. Science 1995;267:988-993.
339. St. Clair MH, Miller WH, Miller RL, et al. Inhibition of cellular α DNA polymerase and herpes simplex virus-induced DNA polymerases by the triphosphate of BW759U. Antimicrob Agents Chemother 1984;25:191-194.
340. St. Clair MH, Richards CA, Spector T, et al. 3'-azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob Agents Chemother 1987;31:1972-1977.
341. Staschke KA, Colacino JM, Baxter AJ, et al. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 1995;214:642-646.
342. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865-1873.
343. Stouffer AL, Acharya R, Salom D, et al. Structural basis for the function and inhibition of an influenza virus proton channel. Nature 2008;451:596-599.
344. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171.
345. Strain MC, Günthard HF, Havlir DV, et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A 2003;100:4819-4824.
346. Strain MC, Letendre S, Pillai S, et al. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol 2005;79:1772-1788.
347. Straus SE, Croen KD, Sawyer MH, et al. Acyclovir suppression of frequently recurring genital herpes. Efficacy and diminishing need during successive years of treatment. JAMA 1988;260:2227-2230.
348. Streeter DG, Witkowski JT, Khare GP, et al. Mechanism of action of 1-β-ribofuranosyl-1,2,4-triazole-3-carboxamide, a new broad spectrum antiviral agent. Proc Natl Acad Sci U S A 1973;70:1174-1178.
349. Sugrue RJ, Hay AJ. Structural characteristics of the M2 protein of influenza A viruses: evidence that it forms a tetrameric channel. Virology 1991;180:617-624.
350. Sullivan V, Talarico CL, Stanat SC, et al. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992;358:162-164.
351. Summa V, Petrocchi A, Bonelli F, et al. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 2008;51:5843-5855.
352. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-1104.
353. Suzuki Y, Kumada H, Ikeda K, et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999;30:743-758.
354. Suzutani T, Ishioka K, De Clercq E, et al. Differential mutation patterns in thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 clones passaged in the presence of acyclovir and penciclovir. Antimicrob Agents Chemother 2003;47:1707-1713.
355. Sweet C, Hayden FG, Jakeman KJ, et al. Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J Infect Dis 1991;164:969-972.
356. Talarico CL, Burnette TC, Miller WH, et al. Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob Agents Chemother 1999;43:1941-1946.
357. Tan K, Liu JH, Want JH, et al. Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A 1997;94:12303-12308.
358. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-1109.
359. The panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/guidelines/.
360. The studies of ocular complications of AIDS research group in collaboration with the AIDS clinical trials group. Combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch Ophthalmol 1996;114:23-33.
361. Thomas E, Feld JJ, Li Q, et al. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 2010;53:32-41.
362. Thompson M, Aberg J, Hoy J, Telenti A, Benson C, Cahn P, Eron Jr J, Gunthard H, Hammer S, Reiss P, Richman D, Rizzardini G, Thomas D, Jacobsen D, Volberding P. Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society-USA Panel. JAMA 308(4):387-402, 2012.
363. Tong X, Chase R, Skelton A, et al. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006;70:28-38.
364. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-450.
365. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000;283:1016-1024.
366. Trkola A, Kuhmann SE, Strizki JM, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A 2002;99:395-400.
367. Tyring S, Barbarash RA, Nahlik JE, et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995;123:89-96.
368. Van Voris LP, Betts RF, Roth FK, et al. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA 1981;245:1128-1131.
369. Varghese JN, McKimm-Breschkin JL, Caldwell JB, et al. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 1992;14:327-332.
370. von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993;363:418-423.
371. Wald A, Corey L, Cone R, et al. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest 1997;99:1092-1097.
372. Ward P, Small I, Smith J, et al. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005;55(Suppl. 1):i5-i21.
373. Weissenhorn W, Dessen A, Harrison SC, et al. Atomic structure of the ectodomain from HIV-1 gp41. Nature 1997;387:426-430.
374. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007;81:2359-2371.
375. Wetherall NT, Trivedi T, Zeller J, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol 2003;41:742-750.
376. Whitcomb JM, Parkin NT, Chappey C, et al. Broad nucleoside reverse transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003;188:992-1000.
377. Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986;314:144-149.
378. Whitley RJ, Gnann JW Jr. Acyclovir: a decade later. N Engl J Med 1992;327:782-789.
379. Whitley RJ, Gnann JW Jr, Hinthorn D, et al. Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. The NIAID Collaborative Antiviral Study Group. J Infect Dis 1992;165:450-455.
380. Whitley RJ, Jacobson MA, Friedberg DN, et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. Arch Intern Med 1998;158:957-969.
381. Whitley RJ, Nahmias AJ, Soong SJ, et al. Vidarabine therapy of neonatal herpes simplex virus infection. Pediatrics 1980;66:495-501.
382. Whitley RJ, Soong SJ, Dolin R, et al. Adenine arabinoside therapy of biopsy-proven herpes simplex encephalitis. National Institute of Allergy and Infectious Disease collaborative antiviral study. N Engl J Med 1977;297:289-294.
383. Wild C, Dubay J, Greenwell TK, et al. Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci U S A 1994;91:12676-12680.
384. Wild C, Greenwell T, Shugars D, et al. The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res Hum Retroviruses 1995;11:323-325.
385. Wild C, Oas T, McDanal C, et al. A synthetic peptide inhibitor of HIV replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A 1992;89:10537-10541.
386. Wild C, Shugars DC, Greenwell TK, et al. Peptides corresponding to a predictive alpha-helical domain of HIV-1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 1994;91:9770-9774.
387. Wild K, Bohner T, Aubry A, et al. The structures of thymidine kinase from herpes simplex virus type 1 complexed with substrates and a substrate analogue. Protein Sci 1997;6:2097-2106.
388. Wlodawer A, Erickson JW. Structure based inhibitors of HIV-1 protease. Annu Rev Biochem 1993;62:543-580.
389. Wlodawer A, Miller M, Jaskólski M, et al. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 1989;245:616-621.
390. Wong JK, Hezareh M, Günthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-1294.
391. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010;139:1218-1229.
392. Wu JC, Warren TC, Adams J, et al. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry 1991;30:2022-2026.
393. Xiong X, Smith JL, Chen MS. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob Agents Chemother 1997;41:594-599.
394. Xiong X, Smith JL, Kim CU, et al. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem Pharmacol 1996;51:1563-1567.
395. Yarchoan R, Klecker RW, Weinhold KJ, et al. Administration of 3'-azido-3'deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet 1986;i:575-580.
396. Yeh RW, Coen DM. Pharmacology of viral infections. In: Golan DE, Tashjian AH Jr, Armstrong EJ, et al, eds. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 3rd ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2012:649-673.
397. Younkin SW, Betts RF, Roth FK, et al. Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine. Antimicrob Agents Chemother 1983;23:577-582.
398. Zahn KE, Tchesnokov EP, Gotte M, et al. Phosphonoformic acid inhibits viral replication by trapping the closed form of the DNA polymerase. J Biol Chem 2011;286:25246-25255.
399. Zennou V, Mammano F, Paulous S, et al. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 1998;72:3300-3306.
400. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.
401. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
402. Zhang Y, Simpson AA, Ledford RM, et al. Structural and virological studies of the stages of virus replication that are affected by antirhinovirus compounds. J Virol 2004;78:11061-11069.
403. Zhang Z, Schuler T, Zupancic M, et al. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 1999;286:1353-1357.
404. Zhang Z-Q, Notermans DW, Sedgewick G, et al. Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc Natl Acad Sci U S A 1998;95:1154-1159.
405. Zhou S, Liu R, Baroudy BM, et al. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 2003;310:333-342.